Exploring the effect of an ABE intervention tool to assist general practices on the implementation of NICE ‘Do-Not-Do' recommendations in people with cardiometabolic multimorbidity. Other
Conditions
Interventions
Current interventions as of 25/04/2025:
The study will be an unblinded, cluster randomised controlled trial to explore whether an ABE package to assist general practices can lead to an improvement in
this will comprise webinars, or videos and podcasts, covering the importance of the ‘Do-Not-Do’ guidelines and how to use and interpret the ABE feedback. Materials relevant to learning, appraisal and
Sponsors
University of Oxford
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Current participant inclusion criteria as of 25/04/2025: Practice inclusion criteria: Primary care practices in England that are members of the Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) network. The Oxford-RCGP RSC has a secure analytics hub based at the University of Oxford (ORCHID-secure) and has >20 million registered patients across >2000 practices. Each GP practice will be selected to participate in the study based on whether their data can reliably be extracted. This is vital for the purpose of being able to refresh the practice dashboard with updated data monthly, as well as for analysis at the end of the study. Patient inclusion criteria: Data from computerised medical records (CMRs) of patients with cardiometabolic multimorbidity will be used to update the practice dashboard, which is part of the ABE package. Data from CMRs will also be used for analysis at the end of the trial to explore the effectiveness of the intervention compared to standard care alone. The data will be collected via the Oxford-Royal College of General Practitioners Clinical Informatics Data Hub (ORCHID) database. The database includes pseudonymised data of computerised medical records for patients registered with GP practices that are members of Oxford-RCGP RSC network. Patients with cardiometabolic multimorbidity will be flagged and have data extracted in participating practices providing they meet the following inclusion criteria: 1. Aged 18-64 years 2. Confirmed diagnosis of two or more cardiometabolic diseases. Previous participant inclusion criteria: Practice inclusion criteria: Primary care practices in England that are members of the Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) network. The Oxford-RCGP RSC has a secure analytics hub based at the University of Oxford (ORCHID-secure) and has >15 million registered patients across >1800 practices. Each GP practice will be selected to participate in the study based on whether their data can reliably be extracted. This is vital for the purpose of being able to refresh the practice dashboard with updated data monthly, as well as for analysis at the end of the study. Patient inclusion criteria: Data from computerised medical records (CMRs) of patients with cardiometabolic multimorbidity will be used to update the practice dashboard, which is part of the ABE package. Data from CMRs will also be used for analysis at the end of the trial to explore the effectiveness of the intervention compared to standard care alone. The data will be collected via the Oxford-Royal College of General Practitioners Clinical Informatics Data Hub (ORCHID) database. The database includes pseudonymised data of computerised medical records for patients registered with GP practices that are members of Oxford-RCGP RSC network. All data for patients that have explicitly opted-out of data sharing will be excluded from the analysis. Patients with cardiometabolic multimorbidity will be flagged and have data extracted in participating practices providing they meet the following inclusion criteria: 1. Aged 18-64 years 2. Confirmed diagnosis of two or more cardiometabolic diseases.
Exclusion criteria
Exclusion criteria: 1. Primary care practices that are not members of the Oxford RCGP RSC network. 2. Patients <18 years old and/or without cardiometabolic conditions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measure as of 25/04/2025: Proportion of patients inappropriately treated as per the NICE ‘Do-Not-Do’ recommendations at baseline, and after implementation of the ABE intervention, measured using the Oxford-Royal College of General Practitioners Clinical Informatics Data Hub (ORCHID) database. Previous primary outcome measure: Proportion of patients inappropriately treated as per the NICE ‘Do-Not-Do’ recommendations at baseline, and 12 months after implementation of the ABE intervention, measured using the Oxford-Royal College of General Practitioners Clinical Informatics Data Hub (ORCHID) database. | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures | — |
Countries
England, United Kingdom
Outcome results
None listed